Autopsy report · NCT05644626

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

“Sponsor determined the data was no longer needed.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

BeiGene

Sponsor type

Industry

Conditions

Solid Tumors

Interventions

BGB-B167; Tislelizumab

Participants

0

Trials that died the same way

• A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001
  “Sponsor considered no further meaningful data was being collected, nor were likely to be collected in the future.” (77% match in meaning)
• Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System
  “Data no longer required to meet regulatory requirements.” (77% match in meaning)
• Manual Therapy/Exercises vs. Physiotherapy/Back School vs. Waiting List in Patients With Chronic Low Back Pain
  “Sponsor did not want to continue the study.” (69% match in meaning)
• The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency
  “Study was not initiated as it is no longer consistent with the Sponsor's development plans.” (68% match in meaning)
• Safety Study of the VEGA UV-A System to Treat Keratoconus
  “The sponsor terminated the study prior to data analysis for financial reasons.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.